• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

In vitro interactions of TNO6 with human plasma.

作者信息

Hecquet B, Adenis L, Demaille A

出版信息

Cancer Chemother Pharmacol. 1983;11(3):177-81. doi: 10.1007/BF00254200.

DOI:10.1007/BF00254200
PMID:6685579
Abstract

The ability of TNO6 to react with human plasma was investigated by in vitro incubation of plasma or plasma fractions with injectable TNO6. HPLC, ultrafiltration and flameless atomic absorption spectrophotometry were used to separate the platinum-containing chemical species and to measure the platinum content. The initial concentration of TNO6 in plasma declines very rapidly. The kinetics of the loss of initial TNO6 is very different from that of cisplatin loss. Most of the TNO6 is bound more quickly to proteins, while a little is transformed to less reactive or nonreactive platinum species. The level of final nonreactive platinum species depends on the particular plasma concerned. In addition, the reactivity of TNO6 towards proteins is very sensitive to Cl- concentration. The usefulness of HPLC for the study of TNO6 kinetics is demonstrated.

摘要

相似文献

1
In vitro interactions of TNO6 with human plasma.
Cancer Chemother Pharmacol. 1983;11(3):177-81. doi: 10.1007/BF00254200.
2
In vitro plasma binding of some second generation antitumor platinum complexes.
Eur J Drug Metab Pharmacokinet. 1985 Jan-Mar;10(1):77-83. doi: 10.1007/BF03189700.
3
Atomic absorption spectrophotometry of free circulating platinum species in plasma derived from cis-dichlorodiammineplatinum(II).顺二氯二氨合铂(II)血浆中游离循环铂物种的原子吸收分光光度法。
Clin Chem. 1978 Jun;24(6):877-80.
4
Interaction of cisplatin and carboplatin with sodium thiosulfate: reaction rates and protein binding.顺铂和卡铂与硫代硫酸钠的相互作用:反应速率和蛋白质结合
Clin Chem. 1986 Apr;32(4):641-5.
5
Comparative protein binding, stability and degradation of satraplatin, JM118 and cisplatin in human plasma in vitro.体外人血浆中沙铂、JM118和顺铂的蛋白质结合、稳定性及降解的比较
Clin Exp Pharmacol Physiol. 2008 Dec;35(12):1440-6. doi: 10.1111/j.1440-1681.2008.05017.x. Epub 2008 Jul 29.
6
Chemical reactivity of cisplatin bound to human plasma proteins.
Cancer Chemother Pharmacol. 1987;20(3):211-2. doi: 10.1007/BF00570487.
7
[Pharmacokinetic properties of platinium derivatives].[铂衍生物的药代动力学特性]
Bull Cancer. 2001 Aug;88 Spec No:S14-9.
8
Clinical pharmacokinetics of carboplatin.卡铂的临床药代动力学
J Clin Pharmacol. 1988 Mar;28(3):208-15. doi: 10.1002/j.1552-4604.1988.tb03134.x.
9
A novel method for speciation of Pt in human serum incubated with cisplatin, oxaliplatin and carboplatin by conjoint liquid chromatography on monolithic disks with UV and ICP-MS detection.一种新方法用于对顺铂、奥沙利铂和卡铂与人血清孵育后的 Pt 进行形态分析,方法是采用整体柱液相色谱联用 UV 和 ICP-MS 进行检测。
Talanta. 2013 Nov 15;116:141-8. doi: 10.1016/j.talanta.2013.05.016. Epub 2013 May 16.
10
In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells.顺铂、洛铂和奥沙利铂在溶液中的小牛胸腺DNA以及培养的人细胞中体外形成DNA加合物的情况。
Carcinogenesis. 1996 Dec;17(12):2763-9. doi: 10.1093/carcin/17.12.2763.

引用本文的文献

1
Platinum concentration in human tumors of head and neck, uterine cervix, and breast following treatment with cisplatin.顺铂治疗后人类头颈部、子宫颈和乳腺肿瘤中的铂浓度。
Cancer Chemother Pharmacol. 1985;15(3):310-2. doi: 10.1007/BF00263908.
2
Protein binding of five platinum compounds. Comparison of two ultrafiltration systems.
Cancer Chemother Pharmacol. 1986;18(2):129-32. doi: 10.1007/BF00262281.
3
Correlation between free platinum AUC and total platinum measurement 24 h after i.v. bolus injection of cisplatin in humans.
Cancer Chemother Pharmacol. 1988;21(1):75-7. doi: 10.1007/BF00262745.
4

本文引用的文献

1
Cisplatin: chemistry, distribution and biotransformation.
Biopharm Drug Dispos. 1981 Jan-Mar;2(1):1-16. doi: 10.1002/bdd.2510020102.
2
Pharmacokinetics and protein binding of cis-dichlorodiammine platinum (II) administered as a one hour or as a twenty hour infusion.
Cancer Chemother Pharmacol. 1980;5(1):21-6. doi: 10.1007/BF00578558.
3
Pharmacokinetic study of cis-dichlorodiammineplatinum(II) (DDP) in the beagle dog: thermodynamic and kinetic behavior of DDP in a biologic millieu.顺二氯二氨铂(II)(DDP)在比格犬体内的药代动力学研究:DDP在生物环境中的热力学和动力学行为
Cancer Treat Rep. 1979 Jan;63(1):59-71.
Tumor-tissue and plasma concentrations of platinum during chemotherapy of non-small-cell lung cancer patients.非小细胞肺癌患者化疗期间肿瘤组织和血浆中的铂浓度。
Cancer Chemother Pharmacol. 1990;27(1):72-5. doi: 10.1007/BF00689280.
5
Modification of the physicochemical and pharmacological properties of anticancer platinum compounds by commercial 5-fluorouracil formulations: a comparative study using cisplatin and carboplatin.商用5-氟尿嘧啶制剂对抗癌铂类化合物物理化学和药理性质的修饰:一项使用顺铂和卡铂的比较研究。
Cancer Chemother Pharmacol. 1992;29(6):461-6. doi: 10.1007/BF00684848.